- Home
- ICU vs TOVX Comparison
ICU vs TOVX Comparison
Compare ICU & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ICU | TOVX |
|---|---|---|
| Founded | 2018 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 16.4M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | ICU | TOVX |
|---|---|---|
| Price | $4.37 | $0.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 118.5K | ★ 24.1M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.00 | N/A |
| Revenue Next Year | $50.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.22 | $0.16 |
| 52 Week High | $4.93 | $1.47 |
Technical Indicators
Market Signals| Indicator | ICU | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 60.51 | 62.90 |
| Support Level | $2.26 | $0.38 |
| Resistance Level | $4.89 | $0.52 |
| Average True Range (ATR) | 0.41 | 0.04 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 66.67 | 56.14 |
Price Performance
Historical ComparisonAbout ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.